Navigation Links
AMRI Announces First Quarter 2013 Results and Raises EPS Guidance for the Year
Date:5/7/2013

n its goal to be profitable without the benefit of royalties or milestones by the end of the year."

Recent Highlights Recent noteworthy announcements or milestones at AMRI include the following:

  • Announced a new five-year service agreement with Ono Pharmaceutical Company, Ltd., which extends a drug discovery and development collaboration between the companies.
  • Signed a long-term agreement with a specialty pharmaceutical company that includes various services for multiple oncology products.
  • First Quarter Conference Call The company will hold a conference call at 10:00 a.m. ET on Tuesday, May 7, 2013 to discuss its quarterly results, business highlights and prospects. During the conference call, the company may discuss information not previously disclosed to the public. The conference call can be accessed by dialing 888-556-4997 (domestic calls) or 719-325-2452 (international calls) at 9:50 a.m. ET and entering passcode 4945957. The webcast will be available live via the Internet and can be accessed on the company's website at www.amriglobal.com. Replays of the webcast can also be accessed for up to 90 days after the call via the investor area of the company's website at www.amriglobal.com/investor_relations/.

    About AMRIAlbany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services. For over 21 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced effi
    '/>"/>

    SOURCE AMRI
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Rigel Announces First Quarter 2013 Financial Results
    2. Mindray Announces First Quarter 2013 Financial Results
    3. Lilly Announces CEO Dr. John Lechleiter to Undergo Scheduled Surgery
    4. Hologic Announces Second Quarter Fiscal 2013 Operating Results
    5. Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer
    6. AG Mednet Announces Partnership with The Methodist DeBakey Heart & Vascular Center Echocardiography Core Lab
    7. Isis Pharmaceuticals Announces the Initiation of a Clinical Study of ISIS-STAT3 Rx in Patients with Liver Cancer
    8. Apollo Medical Holdings Announces Record Fiscal Year-End Results
    9. Atrium Medical Announces 1-year results of the INFUSE-AMI Trial
    10. Premier Home Medical Supply Vendor Med Supply Shop Announces Drive Spring Promotion
    11. Volcano Announces First Quarter Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/30/2014)... , Oct. 30, 2014  CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced an ... lead drug candidate, aldoxorubicin.  The presentation, titled, "Drug ... will be given by Sant P. Chawla ... Center and principal investigator of the Company,s ongoing ...
    (Date:10/30/2014)... -- , La fórmula de leche ... tolerancia a la proteína de leche de vaca  ... leche de la vaca (APLV) es la principal alergia alimentaria ... APLV se trataba eliminando las proteínas lácteas de ... posible adquirir tolerancia oral en un número significativo ...
    (Date:10/30/2014)... Oct. 30, 2014  TWi Pharmaceuticals, Inc. today announced ... States Food and Drug Administration (FDA) on its Abbreviated ... 23 mg, the generic equivalent to Eisai Inc.,s Aricept® ... patients. TWi Pharmaceuticals is preparing to launch ... subsidiary, TWi Pharmaceuticals USA , at ...
    Breaking Medicine Technology:CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3
    ... 28, 2011 Nile Therapeutics, Inc. (Nasdaq: ... novel therapeutics for heart failure patients, today announced plans ... ) on the clinical development of Nile,s proprietary natriuretic ... disease applications. "We are very pleased to ...
    ... Feb. 28, 2011 PAREXEL International Corporation (Nasdaq: ... presenting at the Raymond James Investors Conference in Orlando, FL. ... be making a presentation on PAREXEL at 2:50 p.m.  ET ... of this presentation will be available through the "Investors" ...
    Cached Medicine Technology:Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 2Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 3PAREXEL International to Present at Raymond James Investors Conference 2
    (Date:10/28/2014)... that aims to make personalized medicine a reality for ... across British Columbia. , The "Genomics for Precision Drug ... of its kind in North America. The project is ... (BCPhA), with the research component led by a team ... Sciences (UBC). It will position the pharmacist as the ...
    (Date:10/27/2014)... price tag for informal caregiving of elderly people by ... $522 billion a year, according to a new RAND ... care at minimum wage would cost $221 billion, while ... $642 billion annually. , The study, published online ... estimates about the value of informal caregiving by making ...
    (Date:10/27/2014)... different role than previously thought in the opening and ... out of our cells, researchers at Johns Hopkins report. ... right concentrations of sodium and calcium ions in cells ... processes. The new study reveals that a form of ... channels wide. The finding is likely to bring new ...
    (Date:10/27/2014)... The 2014 Sharp­Brains Vir­tual ... world’s top sci­en­tists and inno­va­tors work­ing on ... via neuroscience-based inno­va­tion. , Indi­vid­u­als and insti­tu­tions ... bil­lion in 2014 in web-based, mobile and ... func­tion. Growth is poised to con­tinue, fueled ...
    (Date:10/27/2014)... Agency (EMA), an EU agency, has gathered information on ... European ADR database, EudraVigilance. Both authorities and pharmaceutical companies ... the database, which provides new knowledge about unknown and ... drug reaction reports on asthma medications approved for – ... (2007 to 2011). In the light of the total ...
    Breaking Medicine News(10 mins):Health News:Genomics helps pharmacists target the right drugs for the right patient 2Health News:Cost of informal caregiving for US elderly is $522 billion annually, study finds 2Health News:200 Experts to Discuss and Shape the Future of Brain Health, Gathered Around a Virtual Table 2Health News:200 Experts to Discuss and Shape the Future of Brain Health, Gathered Around a Virtual Table 3Health News:200 Experts to Discuss and Shape the Future of Brain Health, Gathered Around a Virtual Table 4Health News:Adverse drug reactions in children following use of asthma medications 2
    ... a pregnancy take a general multivitamin supplement in the ... them and their baby, however a recent survey suggests ... in unborn babies but many women do not consider ... based on a recent survey. The survey conducted by ...
    ... has donated $50,000 to Gilda's Club Worldwide, //an organization that ... in a statement: "When children have cancer, or when their ... places they can turn to for support." , ,"Gilda's ... helping children in need, and so I am very happy ...
    ... People suffering from Alzheimer’s disease can have loss of ... to test their visual clarity., ,Alzheimer’s disease affects ... symptoms of the disease are decreasing memory, ability to ... Alzheimer’s disease are often disoriented too much to be ...
    ... may lack a gene called estrogen receptor beta and not ... research funded by National Institute of Environmental Health Sciences reported ... role in moving the egg outside the ovary to be ... is found otherwise throughout in the female reproductive tissues, women ...
    ... people were infected with HIV by 2004.// This puts the prevalence ... South Africa 's total population is 46.9 million. , ... far higher than the estimate of 4.5 million given by the ... ,The health department said that between 6.29 million ...
    ... microRNAs may be responsible for birth defects, cancer and ... Institute have used genetically modified mice to see how ... animals. When the mice were grown without the microRNA ... limbs., ,MicroRNA (miRNA) are small RNA molecules that ...
    Cached Medicine News:Health News:Britney Spears Donates $50 000 To Support Cancer Patients 2Health News:Britney Spears Donates $50 000 To Support Cancer Patients 3Health News:Over Six Million HIV Infected People In South Africa- Finds A Survey 2Health News:Over Six Million HIV Infected People In South Africa- Finds A Survey 3
    0.6mm Tip x10mm Shaft, Straight Shaft, 90 Degree Hook at Tip; overall length 120mm; in Titianium....
    ... SURPASS Perfusion Catheter is indicated ... stenotic portion of a coronary ... for the purpose of improving ... Catheters are also designed to ...
    16mm from Mid-screw to Tips, blunt tips; overall length 110mm; Stainless Steel...
    16mm from Mid-Screw to Blunt Tips, Gently Curved Blades; overall length 120mm; Stainless Steel...
    Medicine Products: